The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 03, 2017
Filed:
Jun. 30, 2014
Applicant:
Signature Therapeutics, Inc., Palo Alto, CA (US);
Inventors:
Thomas E. Jenkins, Half Moon Bay, CA (US);
Julie D. Seroogy, San Carlos, CA (US);
Jonathan W. Wray, San Francisco, CA (US);
Assignee:
Signature Therapeutics, Inc., Palo Alto, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/497 (2006.01); C07K 5/072 (2006.01); A61K 31/155 (2006.01); A61K 31/485 (2006.01); A61K 31/135 (2006.01); A61K 31/195 (2006.01); A61K 31/439 (2006.01); A61K 31/445 (2006.01); A61K 31/451 (2006.01); A61K 31/495 (2006.01); A61K 31/55 (2006.01); A61K 38/05 (2006.01); C07C 215/64 (2006.01); C07C 257/18 (2006.01); C07C 279/18 (2006.01); C07D 211/66 (2006.01); C07D 217/04 (2006.01); C07D 221/26 (2006.01); C07D 223/04 (2006.01); C07D 295/185 (2006.01); C07D 491/08 (2006.01); A61K 47/48 (2006.01);
U.S. Cl.
CPC ...
C07K 5/06121 (2013.01); A61K 31/135 (2013.01); A61K 31/155 (2013.01); A61K 31/195 (2013.01); A61K 31/439 (2013.01); A61K 31/445 (2013.01); A61K 31/451 (2013.01); A61K 31/485 (2013.01); A61K 31/495 (2013.01); A61K 31/55 (2013.01); A61K 38/05 (2013.01); C07C 215/64 (2013.01); C07C 257/18 (2013.01); C07C 279/18 (2013.01); C07D 211/66 (2013.01); C07D 217/04 (2013.01); C07D 221/26 (2013.01); C07D 223/04 (2013.01); C07D 295/185 (2013.01); C07D 491/08 (2013.01); A61K 47/48 (2013.01); A61K 47/48023 (2013.01); A61K 47/48046 (2013.01); A61K 47/48169 (2013.01); C07C 2103/80 (2013.01);
Abstract
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.